T
Taina Turpeenniemi-Hujanen
Researcher at Oulu University Hospital
Publications - 155
Citations - 8330
Taina Turpeenniemi-Hujanen is an academic researcher from Oulu University Hospital. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 48, co-authored 153 publications receiving 7905 citations. Previous affiliations of Taina Turpeenniemi-Hujanen include University of Oulu.
Papers
More filters
Journal ArticleDOI
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Heikki Joensuu,Pirkko-Liisa Kellokumpu-Lehtinen,Petri Bono,Tuomo Alanko,Vesa Kataja,Raija Asola,Tapio Utriainen,R. Kokko,Akseli Hemminki,Maija Tarkkanen,Taina Turpeenniemi-Hujanen,Sirkku Jyrkkiö,Martti Flander,Leena Helle,Seija Ingalsuo,Kaisu Johansson,Anna-Stina Jääskeläinen,Marjo Pajunen,Mervi Rauhala,Jaana Kaleva-Kerola,T. Salminen,M. Leinonen,Inkeri Elomaa,Jorma Isola +23 more
TL;DR: A short course of trastuzumab administered concomitantly with docetaxel or vinorelbine is effective in women with breast cancer who have an amplified HER2/neu gene.
Journal ArticleDOI
Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
Heikki Joensuu,Petri Bono,Vesa Kataja,Tuomo Alanko,R. Kokko,Raija Asola,Tapio Utriainen,Taina Turpeenniemi-Hujanen,Sirkku Jyrkkiö,Kari Möykkynen,Leena Helle,Seija Ingalsuo,Marjo Pajunen,Mauri Huusko,T. Salminen,Päivi Auvinen,Hannu Leinonen,M. Leinonen,Jorma Isola,Pirkko-Liisa Kellokumpu-Lehtinen +19 more
TL;DR: A brief course of trastuzumab administered concomitantly with docetaxel is safe and effective and warrants further evaluation.
Journal ArticleDOI
Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma
TL;DR: The present data shows for the first time that MMP-2 negativity could serve as a marker for favourable prognosis in breast carcinoma patients with a hormone receptor-negative tumour usually associated with high risk.
Journal Article
Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Heikki Joensuu,Jorma Isola,Mikael Lundin,Tiina Salminen,Kaija Holli,Vesa Kataja,Liisa Pylkkänen,Taina Turpeenniemi-Hujanen,Karl von Smitten,Johan Lundin +9 more
TL;DR: The erbB2 status was superior to ER as a prognostic factor in these tumors and was associated with >90% 9-year distant disease-free survival, irrespective of histological grade.
Journal ArticleDOI
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
Harri Sihto,Harri Sihto,Johan Lundin,Johan Lundin,Mikael Lundin,Tiina Lehtimäki,Ari Ristimäki,Ari Ristimäki,Kaija Holli,Liisa Sailas,Vesa Kataja,Taina Turpeenniemi-Hujanen,Jorma Isola,Päivi Heikkilä,Heikki Joensuu,Heikki Joensuu +15 more
TL;DR: Breast tumor biological subtypes have a tendency to give rise to first distant metastases at certain body sites, and several primary tumor proteins were associated with homing of breast cancer cells.